SecBot SecBot
PRESS-RELEASE ·Filed Mar 10, 2026

TARA

Protara Therapeutics
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor upcoming catalysts: regulatory update for LMs in 1H 2026, interim THRIVE-3 data in 2H 2026, and completion of BCG-Unresponsive cohort enrollment in ADVANCED-2. The strong clinical data and extended runway reduce near-term dilution risk and increase probability of regulatory success.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.71
T+0 close · Mar 10, 2026 · via day close
Latest settled
−26.09%
T+60 · $4.22
Vs SPY
−37.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 10 $5.71entry
  2. T+1 · 8mo ago −1.93%α −1.82% · $5.60
  3. T+5 · 8mo ago −4.55%α −3.65% · $5.45
  4. T+20 · 7mo ago −8.58%α −8.43% · $5.22
  5. T+60 · 6mo ago −26.09%α −37.50% · $4.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protara Therapeutics reported strong interim clinical data for TARA-002 in non-muscle invasive bladder cancer (NMIBC), showing a 68% complete response rate at six months in BCG-Unresponsive patients, alongside Breakthrough Therapy and Fast Track designations for lymphatic malformations. The company raised $86.3 million in a public offering, extending its cash runway into 2028, despite increased R&D and G&A expenses leading to a wider net loss. No revenue was generated as the company remains pre-commercial.

Key Financial Metrics

EPS
$-1.34
Deal Value
$86.3M

Key Facts

  • TARA-002 demonstrated 68.2% complete response rate at six months in BCG-Unresponsive NMIBC patients (22 evaluable patients)
  • Breakthrough Therapy and Fast Track designations received for TARA-002 in lymphatic malformations (LMs)
  • Completed $86.3 million public offering, bringing cash, cash equivalents, and investments to $197.9 million as of December 31, 2025
  • Cash runway now extends into 2028, funding key milestones including ADVANCED-2/3 and THRIVE-3 trials
  • Net loss widened to $57.4 million in 2025 from $44.6 million in 2024 due to higher R&D and G&A spending
  • No revenue reported, company remains clinical-stage with no commercial products

Financial Impact

Increased annual net loss by $12.8 million to $57.4M; raised $86.3M in gross proceeds, boosting cash reserves by ~120%

cashnet_lossr_and_d_expenseg_and_a_expense

Risk Factors

  • Clinical-stage biotech with no revenue; valuation dependent on trial outcomes
  • Widening losses reflect advancing trials, but long-term profitability remains uncertain
  • Market volatility could impact ability to raise capital if runway needs extension

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3252699

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 10, 2026